Get started
Author

Deepa Rangachari

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
2015 · Deepa Rangachari, Norihiro Yamaguchi, et al. · Lung Cancer · 540
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
2019 · Anna F. Farago, Beow Y. Yeap, et al. · Cancer Discovery · 239
Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
2017 · Paul A. VanderLaan, Deepa Rangachari, et al. · Lung Cancer · 190
Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
2021 · Kartik Sehgal, Ritu R. Gill, et al. · JAMA Network Open · 166
PDF
Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival
2011 · George J. Arnaoutakis, Deepa Rangachari, et al. · Journal of Gastrointestinal Surgery · 158
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
2015 · Meghan Shea, Daniel B. Costa, et al. · Therapeutic Advances in Respiratory Disease · 157
PDF
Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
2017 · Deepa Rangachari, Paul A. VanderLaan, et al. · Journal of Thoracic Oncology · 127
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
2019 · Deepa Rangachari, Ciric To, et al. · Journal of Thoracic Oncology · 97
When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
2019 · Kim DeLeonardis, Lauren Hogan, et al. · Journal of Oncology Practice · 94
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
2018 · Lorena Ostios-Garcia, Jennifer Faig, et al. · Journal of Thoracic Oncology · 91
PDF
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
2019 · Rebecca Karp Leaf, Christopher Ferreri, et al. · American Journal of Hematology · 86
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
2015 · Susan E. Jorge, Sol Schulman, et al. · Lung Cancer · 80
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
2020 · Pedro E.N.S. Vasconcelos, Carol Gergis, et al. · JTO Clinical and Research Reports · 79
PDF
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
2018 · Vanda F. Torous, Deepa Rangachari, et al. · Journal of the American Society of Cytopathology · 64
Integrating Palliative Care in Oncology
2013 · Deepa Rangachari, Thomas J. Smith · The Cancer Journal · 61
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
2018 · Susan E. Jorge, Antonio R. Lucena-Araujo, et al. · Clinical Cancer Research · 60
Tumor biomarker testing in non-small-cell lung cancer: A decade of change
2018 · Paul A. VanderLaan, Deepa Rangachari, et al. · Lung Cancer · 60
EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review
2016 · Yuri Sheikine, Deepa Rangachari, et al. · Clinical Lung Cancer · 56
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
2018 · Kartik Sehgal, Rushad Patell, et al. · Translational Cancer Research · 55
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
2020 · Kartik Sehgal, Andreas Varkaris, et al. · Journal for ImmunoTherapy of Cancer · 53
PDF
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
2020 · Ana Pertejo-Fernandez, Biagio Ricciuti, et al. · Lung Cancer · 46
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
2020 · Julia K Rotow, Daniel Botelho Costa, et al. · Journal of Clinical Oncology · 41
Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature
2019 · Camille R. Petri, Rushad Patell, et al. · Respiratory Medicine Case Reports · 41
Molecular Testing Turnaround Time for Non–Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis
2017 · Marcello DiStasio, Yigu Chen, et al. · Clinical Lung Cancer · 38
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
2023 · Daniel Sentana-Lledo, Emmeline Academia, et al. · Translational Lung Cancer Research · 35
PDF
Works count: 186
Citation count: 3,469
H-index: 29
I10-index: 55
Year
Topic
Type